Gilead’s RA Hopeful Filgotinib Hit By Complete Response Letter
FDA Concerned About High Dose And Testicular Side Effects
Complete Response Letter is a major setback for Gilead and its partner Galapagos.
You may also be interested in...
Keeping Track: US FDA Has Clinical Questions For Tricida, Gilead And BioMarin; Enspryng And Winlevi Approved
The latest drug approval and decision news from the Pink Sheet’s US FDA Performance Tracker.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical sector.
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.